|
NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel, immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Through its proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology (FIND-IO), platform, the Company is studying various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Its product candidates include NC318, NC410, NC762 and NC 525. NC318, is an immunomedicine against a novel immunomodulatory protein called Siglec-15. NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor. NC762, is an immunomedicine targeting an immunomodulatory molecule called human B7 homolog 4 protein. NC525, is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia.
Number of employees : 87 people.
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
Stock A |
1 |
27,774,536 |
25,331,962 |
91.2% |
0 |
0.0% |
91.2% |
|
|
Name | Equities | % | OrbiMed Advisors Private Equity | 2,711,013 |
9.76% | Sofinnova Investments, Inc. | 2,671,856 |
9.62% | Pfizer Inc. | 1,970,759 |
7.10% | Lord, Abbett & Co. LLC | 1,764,147 |
6.35% | Eli Lilly and Company | 1,704,391 |
6.14% | K2 & Associates Investment Management, Inc. | 1,581,311 |
5.69% | Millennium Management LLC | 1,449,885 |
5.22% | Great Point Partners LLC | 999,666 |
3.60% | Hillhouse Investment Management Ltd. (Hong Kong) | 978,570 |
3.52% | The Vanguard Group, Inc. | 903,098 |
3.25% |
|
Company contact information |
|
NextCure, Inc. 9000 Virginia Manor Road Suite 200 Beltsville, MD 20705 Phone : +1.240.399.4900 Web : http://www.nextcure.com
|
|
|
Sector Bio Therapeutic Drugs
| | 1st jan. | Capi. (M$) |
 | NEXTCURE, INC. | 17.02% | 46 |
| | | |
 | VERTEX PHARMACEUTICALS | 11.31% | 82 136 |
 | REGENERON PHARMACEUTICALS, INC. | 2.96% | 78 655 |
 | WUXI APPTEC CO., LTD. | 15.12% | 41 845 |
 | BIONTECH SE | -4.37% | 34 142 |
 | BEIGENE, LTD. | 16.46% | 26 628 |
 | GENMAB A/S | -9.49% | 25 417 |
 | ARGENX SE | -0.49% | 20 887 |
 | SAREPTA THERAPEUTICS, INC. | -6.73% | 10 609 |
 | NEUROCRINE BIOSCIENCES, INC. | -9.34% | 10 410 |
 | LEGEND BIOTECH CORPORATION | 0.42% | 8 392 |
 | HALOZYME THERAPEUTICS, INC. | -10.16% | 6 912 |
 | ASCENDIS PHARMA A/S | -1.09% | 6 764 |
 | KARUNA THERAPEUTICS, INC. | -0.76% | 6 701 |
 | REMEGEN CO., LTD. | 11.49% | 5 929 |
 | EXELIXIS, INC. | 8.42% | 5 609 |
 | CEREVEL THERAPEUTICS HOLDINGS, INC. | 9.16% | 5 398 |
 | AKESO, INC. | 13.14% | 5 223 |
 | MADRIGAL PHARMACEUTICALS, INC. | -3.11% | 5 018 |
 | PHARMAESSENTIA CORPORATION | 2.52% | 4 964 |
 | INTRA-CELLULAR THERAPIES, INC. | -11.21% | 4 450 |
Connections : NextCure, Inc.
|